News

Stories

Four in ten cases of prostate cancer diagnosed late

Male cancer charity and Tackle Partner Member Orchid report today that four in ten cases of prostate cancer are diagnosed late.

Read the full story here.

Tackle takes issue with the British Medical Journal

A recent issue of the British Medical Journal (BMJ)  - read widely by GPs - had an article about the outdated US PIVOT trial. Fortunately, Chris Booth - who is on our Clinical Advisory Board - saw it and responded as follows:

"Quoting from the USA's PIVOT trial on Prostate Cancer (PCa) is another example of conclusions
being drawn from an outdated American study that is completely inelevant so far as current UK
urological practice is concerned. Worse still, it deflects GPs from giving balanced information to men
quite righly seeking PSA screening for PCa. Anyone wishing for an objective understanding of the
flaws in PIVOT should read D'Amico's "Long-term Follow-up of PIVOT Argues for lmmediate
Treatmenl of Men With Unfavourable-Risk and Possibly High-Volume, Low-Risk Prostate cancer".

"So far as UK practice is concerned, those seeking to give unbiased, objective, up-to-date
information on screening should note the substantial falls in PCa mortality - over 40% - achieved in
European screening programmes (eg Gothenburg and Rotterdam) compared with our dreadful annual
mortality of over 11,800 men. Furthermore, what does deserve publicity are the highly acclaimed UK
results from the PROMIS, PRECISION and ProtecT studies. These, together with the results of the
4th Nationat Prostate Cancer Audit, have demonstrated that the "harms" of PCa screening - "overdiagnosis and over-treatment" - have been largely overcome in current UK clinical practice.
The audit shows that there is a widening gap between our high mortality/poor screening statistics and
the excellent care now available to men lucky enough to have screen-detected, early, curable PCa. lt
also sadly confirms that over 50% of UK men still present with advanced and probably incurable PCa,
16% with metastases.

"The conclusion has to be that in the absence of better options, application of PSA screening
according to accepted national and international guidelines for properly informed men is the best way
we can lower our unacceptable death rate for this thoroughly unpleasant cancer."

We are very grateful for Chris' help.

Roger Wotton discusses prostate cancer on Dacorum radio

Tackle Chairman Roger Wotton was interviewed this evening on Radio Dacorum this evening.

It was a great session and Roger talked about prostate cancer symptoms, local PSA testing, our new campaign "Cycle to the Moon and Save a Dad", other partners we work with like Graham Fulford and Orchid, media stories and a few personal observations.

Listen to the interview here. It starts 6 minutes and 20 seconds in. (You may find it easier to download it and listen but it is 34Mb in size).

Access to Cancer Medicines Coalition calls for patient safeguarding during Brexit

Tackle Prostate Cancer has joined forces with other national cancer charities and patient representative organisations in calling for the interests of people affected by cancer to be safeguarded throughout the second phase of Brexit negotiations.

In a letter to Jeremy Hunt MP, Health Secretary and Greg Clark MP, Business Secretary, the Access to Cancer Medicines Coalition has warned that we must ensure the UK retains prompt access to the most innovative cancer treatments and the ability to collaborate on the development of new drugs through clinical trials.

The Coalition stated to Ministers that EU-UK regulatory alignment is critical if we are serious about improving outcomes for people affected by cancer in the UK.

Yesterday, Brexit negotiators negotiators Michel Barnier and David Davis agreed on a "large part" of the agreement that will lead to the "orderly withdrawal" of the UK. Tackle Prostate Cancer and the Access to Cancer Medicines Coalition will continue to raise awareness of these issues, ensuring prostate cancer patients and their families do not fall between the cracks of any transitional period agreements.


About the Access to Cancer Medicines Coalition

The Access to Cancer Medicines Coalition (ACMC) brings together 24 cancer charities and patient representative organisations. Its aim is to ensure that cancer patients have timely access to the most clinically effective medicines for their condition on the NHS, and using our combined knowledge, experience and contact with people affected by cancer we will ensure that the patient voice is strongly heard in both public conversations and official decision-making relating to access.

Tackle Takes Issue with Cancer Research UK

Cancer Research UK published yesterday an article about how a one-off PSA test for prostate cancer is doing men more harm than good and does not save lives.

Tackle Chairman Roger Wotton commented: "The PSA test is the only test men have today. It's not perfect, but what we need is a more informed approach to PSA testing on the part of GPs and a realisation that today's clinical  practices do not result in overdiagnosis and overtreatment as was the case many years ago. The problem is,  if men wait until they ahave symptoms before they ask for a test, some 30 per cent will already have some form of advanced cancer. Yes, one PSA test can be inconclusive but what's important is the change in PSA levels. So we need a series of tests properly supported and counselled by GPs. Until a more definite test comes along, let's not deny men a chance to avoid this terrible disease".

If you agree with Roger, please comment on Cancer Research UK's article.

 

Tackle launches inaugural campaign 'Cycle to the Moon' to help raise awareness of prostate cancer

Tackle Prostate Cancer, the voice of prostate cancer patients and their families in the UK, has today announced their inaugural national cycling event ‘Cycle to the Moon, Save a Dad’ – a major fundraising initiative that will encourage people of all ages to get on their bikes and raise awareness and  money for the fight against prostate cancer.

Cycle to the Moon is a chance for members of the public to show their support through their cycling miles either on the roads, in the gym, at home or on outdoor trails from  now to the end of June 2018. The event is open to all ages regardless of ability. It is designed to be a fun, healthy activity raising funds on behalf of Tackle Prostate Cancer as well as encouraging the next generation to participate. It also aims to raise awareness and encourage men at risk of prostate cancer to get tests and earlier diagnosis. The campaign’s target is £250,000 –  £1 for every mile between Earth and the Moon.

Roger Wotton chairman of Tackle Prostate Cancer says: "We know how devastating the diagnosis of prostate cancer can be.  Raising awareness and funds through this  campaign will hopefully see more men being tested earlier, and help accelerate a reduction in mortality figures. Prostate cancer doesn’t just affect the man diagnosed – it affects his whole family."

Tackle Prostate Cancer is a patient-led charity addressing the real issues people face when they are diagnosed with prostate cancer, and helping people to cope with their diagnosis and treatment. As a National Federation, Tackle has 90 support groups across the country, representing some 15,000 members.

Cycle to the Moon ambassador, vocal coach and TV presenter David Grant, said:

“Prostate cancer does not care who it affects or the devastation it causes to patients and their families. It's a cause close to my heart as my cousin was diagnosed, so I want to urge you to make a difference and get on your bikes and clock up some miles. One man dying every 45 minutes is a startling figure and we all need to do what we can to reduce mortality figures. This is a chance for members of the public to fight this cancer. The event is open to all ages regardless of abilities, it is designed as a fun and healthy activity whilst at the same time raising funds for Tackle Prostate Cancer."

Prostate cancer is now a bigger killer than breast cancer. making prostate cancer the third biggest cancer killer in the UK. Every penny raised will make a difference, lives will be saved and more people will be aware of the need to be tested. The money will help the charity continue to meet its objectives of campaigning on behalf of patients and raising awareness in the community. It will also enable the ‘Save a Dad’ initiative to be followed through in secondary schools where the aim is to get a discussion on prostate cancer in the National Curriculum, just as breast cancer is included today. Working through secondary schools Tackle would like to make teenagers aware that prostate cancer will impact 1 in 8 of their dads. The charity hopes that by educating the next generation about the importance of men being tested earlier it can help “Save a Dad”.

Professor Frank Chinegwundoh MBE, Consultant Urological Surgeon, Barts Health NHS Trust, Chairman, Tackle Clinical Advisory Board said: “Prostate cancer is the most common cancer in men in the UK.  Unfortunately many men are unaware of this fact and unaware that there is a blood test, PSA, that is an indicator of their risk.  The 'Cycle to the Moon, Save a Dad' initiative will raise children's awareness and thus their fathers. Undoubtedly, lives will be saved.  Knowledge is power.”

Lord Rose, Ambassador for Tackle Prostate Cancer said: "One in eight men in the UK will develop Prostate Cancer. Tackle's initiative 'Cycle to the Moon, Save a Dad' is an exciting fundraising event which aims, through schools, to raise awareness in the next generation and hopefully see more men at risk of prostate cancer having an earlier diagnosis."

If you would like to get involved please go to the Cycle to the Moon website  where you can download a fundraising pack full of great ideas and tips to get peddling for the fight against prostate cancer.

Email: saveadad@tackleprostate.org

Roger Wotton attends ESO Masterclass in Lisbon

Tackle Chairman attended the ESO Masterclass which took place in Lisbon from 23 to 25 February 2018. A summary of the event is below:

Around 50 delegates from all over Europe got a warm welcome in Lisbon by ESO. When the sun was shining outside, the 3rd Masterclass in Cancer Patient Advocacy had a flying kick-off after some welcoming words from Kathy Redmond, Masterclass coordinator.

Amongst the delegates was countries as Turkey, Israel, Slovak rep., Slovenia, Serbia, Bulgaria, Czech rep. , Poland and Latvia  and this trend has to increase so we have more representation from the other side of the “12° East line” .  During the conference a number of “experts” were invited to present different ways for us to improve in networking and leadership skills. Some of these presentations was too theoretical and missed somewhat the target. In other blocks people from different patient organisations were invited to present their experience from the real life. What difficulty they had experienced in xx country? These presentations give you much more “take home” information than a theoretical study. During the last session the concept of “Community advisory Board” was presented and can be used in special situations but is for the moment not applicable for our situation.

Highlights: 

Mike Hudson Compass Partner – Workshop for “Creating effective Boards”.

We all felt rather familiar with questions as governance, succession planning as well as what a board member should do.

Jean-Pierre THIERRY France – Closing the gap between the costs and benefits of cancer medicine.

The Lancet, 2010 report fails to show that the long-term outcomes of robot-assisted surgery are superior to those of conventional procedures shows a good example of costs without the benefit.

The crisis of confidence in the results of clinical trials is demonstrated by

• Unreported negative results

• Bias in patient selection, statistical methods, interpretation

• Non-independent authors/Conflicts of Interest

Sandra Bull 360’ communication

Here we got the chance to test ourselves in different crisis communication scenarios where it is important to be prepared and not to panic when the difficult question is coming your way.

Bettina Ryll melanoma Network Europe- How to read an original scientific publication

We all know the difficulties to get the important info out of those many scientific publications we see all the time. What’s “fake news” and what is correct?

Ian Galloway MPNE Ocular/Rare - MRIs for Post-Primary Uveal Melanoma Patients in Scotland

Scottish ocular melanoma patients are unable to receive MRI scans after primary diagnosis

To win the fight you sometimes have to play dirty and be persistent in what you believe in. Get some strong allies.

Maja Kocic Lymphoma Coalition Europe and Serbia

Survey “Lymphoma care in Serbia”

What is not measured has no chance to be improved!  To better understand issues and challenges that lymphoma/CLL patients in Serbia face and to improve access to novel and standard treatments they developed their own report by highlighting the things important from the Serbian patient point of view

In the survey 527 out of 600 completed the study but  63% were wrongly diagnosed, 18% were diagnosed with wrong Subtype  and only 19% was correctly diagnosed for their initial symptoms.

With a rather simple adaption of an existing survey it was in Serbia giving a very good result to be a base for future action in survivorship care.

Dr Stefania Mostaccioli Lega per la Neurofibromatosi 2 Onlus- When you have to fight against fixed positions

When you have to fight “reclassification of Rare diseases” by the Ministry of Health bureaucrats you have to find some expert that stands up for your course and help you in the fight.

“It is easier to break an atom than a prejudice”  - A. Einstein

Summary

A worthwhile masterclass although there was rather too much “tell” and not enough time for discussion. A number of presenters overran on time and panel discussions did not allow sufficient time for questions from the floor.  It might also have been better to hear more personal stories of patient advocacy from attendees rather than presentations form the steering committee.  

Stephen Fry talks about his recent prostate cancer journey

Stephen Fry  announced today that he has been diagnosed with prostate cancer.

In a full and frank video, he explains in detail about his particular diagnosis and how he was treated.

Importantly, he strongly encourages men to get their PSA checked. As Tackle followers will know, early detection is one of key objectives through our Get a Score on the Board campaign. As we say in that campaign, "you'd be nuts not to".

Tackle writes to NHS England highlighting bicalutamide availability problem

Tackle Chairman Roger Wotton has sent a joint letter with PCUK to NHS England to highlight the diificulty that men are facing in getting access from pharmacists to the off-patent treatment bicalutamide, as well as several other generic treatments.

Read the letter in full.

TK Maxx Supports Tackle

Tackle Chairman Roger Wotton is presented with a cheque from the fashion retailer TK Maxx in Coventry. 

TK Maxx selected Tackle as one of their community charities following the diagnosis of one of their senior managers.

We really appreciate the support.

Report from Roger Wotton on Prostate Cancer Europe Round Table

Tackle Chairman Roger Wotton attended the Prostate Cancer Europe Round Table discussion held in Brussels on 23 January 2018. He reports:

This was an event that delivered a lot more than expected in terms of alignment and positivity.  Thirty two attendees represented countries from Sweden in the north to Malta in the south and Ireland in the west to Romania in the east. Five pharmaceutical companies attended, along with representatives from the World Health Organisation and the European Parliament.  Keeping order in his consummately professional style was Prof. Hendrik van Poppel.

Overall one was left with a feeling of the management of prostate cancer certainly moving forward, at least in terms of clinical practice if not entirely in terms of uniform progress at a pan-European level.  It was encouraging to see the patient viewpoint being reinforced.

 Increasing support for the inevitable march towards prostate cancer screening was welcome, although “more informed PSA testing” might be a more accurate description of where we are today.  This at least addresses the out of date criticism of over-diagnosis and over-treatment, which was encouraging.  More informed testing was seen to lead to earlier diagnosis and lower mortality, but more needs to be done to at least discuss the relevant risk factors leading to an agreed testing regime. This was not universally being applied.  

There was no shortage of mention about leading edge therapies, but this is where there is some degree of disparity across Europe. This was also noticeable in the wide variation of incidence and mortality rates we are still witnessing.

From the European Commission point of view we heard about the vast sums of money (some €70 Billion) being allocated to cancer projects across Europe, with Horizon 2020 being a beacon for improving cancer outcomes. For prostate cancer, somewhere between 90 and 100 projects are currently being supported with a spend of €130 million.

The WHO Europe perspective highlighted 76,000 deaths p.a. from prostate cancer across Europe and many risk factors still being poorly understood.

The EAU White Paper was discussed and highlighted the cost of some €600,000 p.a. for drugs to treat a hormone-relapsed metastatic patient to achieve a 2 year improvement in survival.  It raises the question as to whether we need to treat all patients with this type of therapy.

A good discussion followed on prostate cancer centre of excellence or “reference centres” as a way of ensuring equality of diagnosis and treatment.  It would seem cultural differences might get in the way, but there are examples of where more sharing of facilities can work : the use of video and publishing outcomes in the UK ; the shared decision planning system in use in Germany, always with a second opinion factored in.

As the discussion turned to a roundtable on how individual countries were faring some interesting points were raised:

  • The great step forward in robotic surgery, even though there are some countries with no robots (Northern Ireland for example).  Italy has over 100 robots and 80% of prostatectomies in Sweden are now robotic. Question – does this mean newly qualified urologists become robot-dependant and not able to carry out general open surgery? In addition, quality control is required for all surgeons carrying out robotic surgery;
  • We are seeing fewer and fewer radiotherapy fractions being given and at the same time advances in scanning techniques with Choline PET scans being superseded by PSMA scans  where (in Germany) the delivery of the therapy goes alongside the scan, although they are  aware of some potential toxicity issues; 
  • An interesting point was raised by Ireland in terms of health economics where we should be looking more closely at outcomes which cost the health service a great deal of money. The best treatment may not have the best outcome for the patient; 
  • It was seen as a real pity that for all the advances in treatment of breast cancer, prostate cancer is still seen as the poor relation.  What can we learn from breast cancer screening and treatment?;
  • It is encouraging to see the increasing use of MRI scans (or mpMRI scans) prior to biopsy, or maybe even working towards a scan before a PSA test?  Evidence of the value of scanning prior to a TRUS biopsy is piling up every week.  The big issue here is the inconsistency in quality of radiologists who need to be fully trained to use the new technology;
  • There was a lot of interest in “big data”, having quality data collected across Europe to be able to compare progress and incidence at each stage. Even getting the results of PSA tests into databases would be an improvement. This was linked also to creating a network between doctors to support the three pillars of information, education and monitoring.  Furthermore, it would improve sharing and standardised reporting. Meaningful outcome measure would have to be agreed.

Overall, a very worthwhile roundtable event where Europa Uomo should be strongly represented in the future.

Ipswich Town Legend Titus Bramble has a PSA Test!

One of our main aims is to encourage early detection of prostate cancer. 1 in 8 men will develop prostate cancer and for black men that risk is 1 in 4.

Recently, ex-Ipswich Town legend Titus Bramble had a PSA test to encourage more men in the black community to get themselves tested.

Well done Titus!

National Prostate Cancer Audit Annual Report 2017

The National Prostate Cancer Audit (NPCA) is the first national clinical audit of the care that men receive following a diagnosis of prostate cancer. It is designed to collect information about the diagnosis, management and treatment of every patient newly diagnosed with prostate cancer in England and Wales, and their outcomes.

The 2017 Report has just been published. Or you can read an Executive Summary of the 2017 Report.

Roger Wotton, Chairman of Tackle Prostate Cancer commented: "This is the fourth annual National Prostate Cancer Audit report.  Tackle continues to play a part in the process. I am a member of the Clinical Reference Group, representing patients' interests and Professor Heather Payne, who is the Oncological clinical lead, is a member of Tackle’s Clinical Advisory Board.  Although this version is primarily produced for a clinical audience, a summarised, more general version will be available in the Spring of 2018. Nevertheless, this report is worth reading for the improvements we are seeing in over-treatment and clinical practice. You can also find the data for your own NHS Trust"

The NPCA is managed as a partnership between a team of clinical, cancer information and audit experts from the British Association of Urological Surgeons, the British Uro-oncology Group, the National Cancer Registration Service and The Royal College of Surgeons’ Clinical Effectiveness Unit.

Roger Wotton - Why the Walnut?

Roger Wotton, Chairman of Tackle Prostate Cancer, explains why we are using the walnut as a symbol in our new Save a Dad! campaign. Watch the video now.

Tackle are developing the Save a Dad! initiative started by Tackle member Leighton Hospital Support Group together with a school in Crewe.  It is encouraging to see the next generation learning about prostate cancer.  Kids talking to dads is another way of raising awareness! We really hope that this could become something that every school in the country would get involved with as it would dovetail well with Tackle's campaign to "get a score on the board".

Tackle Tribute Testing

As a result of Jackie Dijon of JPS Promotions contacting our colleagues in the North West, the tribute acts of Chris Perry (Phil Collins) and Andy Lee (Simply Red) volunteered for a PSA test at Delamere Golf Club. See their video explaining why they're supporting Tackle.

Along with two of the crew, and courtesy of Leighton Hospital Prostate Cancer Support Group, the guys were keen to show their personal support for Tackle and for all that our groups are doing.

Read about the UK tour "An Evening with Phil Collins and Simply Red with Chris Perry and Andy Lee" -  tribute acts in aid of prostate cancer this year and next year.

John Coleman, our NW co-ordinator and a Tackle trustee is our contact point. 

Report on NHS England’s Cancer transformation programme published

You can read the progress report from NHS England’s Cancer transformation programme here.

The report details the investment the NHS is making in cancer transformation, including £130m over the period 2016/18 in new and upgraded radiotherapy equipment and £200m over the next two years to accelerate rapid diagnosis and enhance patients’ quality of life.

The report describes progress across the field including:

  • Modernisation of radiotherapy equipment throughout the country.
  • New models of care introduced to ensure cancer is diagnosed earlier and improve survival.
  • Establishment of Cancer Alliances across the country to bring together clinical leaders, healthcare workers, patients and charities for better coordination of care.

Achieving World-Class Cancer Outcomes – Progress Report 2016-17 describes the significant advances the National Cancer Programme has made over the past year as it moves towards the full delivery of the NHS five-year national cancer strategy.  The strategy was developed in 2015 by an Independent Cancer Taskforce that was asked to deliver the vision set out in the NHS Five Year Forward View.

As well as the work on new models and clinical pathways, the 2017 progress report also details action on standards and metrics.  Five pilot sites are now testing a new faster diagnosis standard that will ultimately ensure patients receive a cancer diagnosis or an “all clear” verdict within 28 days. 

A new quality of life metric – the first anywhere in the world – is currently being tested in multiple sites around England.  Its purpose is to measure long-term outcomes for patients once treatment has been completed.

Cally Palmer, the NHS National Cancer Director, said:

“Cancer survival rates have never been higher than they are today and patients are reporting a very good experience of cancer care. 

“I am confident the NHS can deliver the recommendations of the Cancer Taskforce and I am certain these recommendations will improve survival rates even further, enhance quality-of-life for cancer patients and ultimately provide the very best cancer services to patients everywhere.”

Advanced Prostate Cancer Q&A on Video

If you've got some questions that need answering about advanced prostate cancer, try these two online videos:

Advanced Prostate Cancer - Video 1

Advanced Prostate Cancer - Video 2

Management of Patients with Advanced Prostate Cancer

The European Association of Urology, via publisher Elsevier B.V., has reported on The Advanced Prostate Cancer Consensus Conference APCCC 2017

BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics.

OBJECTIVE: To present the report of APCCC 2017.

DESIGN, SETTING, AND PARTICIPANTS: Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; "oligometastatic" prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process.

RESULTS AND LIMITATIONS: Voting is based on panellist opinion, and thus is not based on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data.

CONCLUSIONS: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them.

PATIENT SUMMARY: The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process.

To read the report in full, click here.

New Diagnostic Blood Test will help target drugs for men with advanced prostate cancer

Tackle Trustee Hugh Gunn was interviewed on ITV this week about a new Diagnostic Blood Test which costs less than £50 and can predict whether patients with advanced prostate cancer are likely to respond to certain drugs and whether they might be better served by alternative therapy.

The blood test identified a particular gene which is resistant to the drug. This test could save the NHS thousands of pounds.

Watch Hugh's interview here.

Prostate cancer screening reconsideration by the USPSTF in the USA

In 2012 the influential United States Preventive Services Task Force (USPSTF) decreed that there was no value in PSA testing for prostate cancer as the “harms” of screening outweighed the “benefits” in terms of lives saved.  This put the USPSTF at loggerheads with most expert American urological opinion but nevertheless resulted in a fall in PSA screening.  The USPSTF was heavily criticised for having no prostate cancer specialists on its panel and also for failing to identify black African Americans and men with a family history of prostate cancer as being in special risk categories that require a proactive, informed approach to screening.

Since 2012 the proportion of American men presenting with advanced prostate cancer has risen and as more and more screening trials and advances in clinical practice are reported, the USPSTF’s position has become increasingly isolated.

It is therefore of considerable relief to hear that the USPSTF has drafted recommendations that support “discussion-backed decisions for men aged 55-69 based on clinician-patient discussion” that allow patients to make an informed decision based on up to date trial evidence and advances in clinical practice that have significantly reduced the risks of “over- diagnosis” and “over-treatment”.

It is to be hoped that the UK’s National Screening Committee will similarly move to a more positive stance on screening.

Tackle joins with APPGC to raise awareness of the importance of improving local one-year survival rates

Tackle were pleased to be involved with the All-Party Parliamentary Group on Cancer (APPGC) which has written to all CCGs in England to highlight the important role they have in improving one-year survival rates, and to offer support in helping to achieve this. Read the letter.

We fully support John Baron MP, Chairman of the APPGC who said: “If we are going to improve cancer survival rates, we must improve early diagnosis. By writing to CCGs we hope to further raise awareness of this issue, and encourage them to drive forward improvements so that thousands more people are able to survive cancer.

“We have also written to offer our support as we are conscious that CCGs do not have responsibility for broad national issues, such as the workforce. The APPGC’s summer Parliamentary reception, which recognises the 20 CCGs which have most improved their one-year figures, presents a further opportunity to engage.”

← View older stories